Csf1R inhibition attenuates experimental autoimmune encephalomyelitis and promotes recovery

Area of Science:

• Neuroimmunology
• Central Nervous System (CNS) Disorders

Background:

• Multiple sclerosis (MS) involves chronic autoimmune damage to the CNS, characterized by demyelination and neurodegeneration.
• Microglia and infiltrating macrophages are key drivers of this inflammatory damage and disease progression in MS.

Purpose of the Study:

• To investigate the therapeutic potential of ablating microglia and macrophages in experimental autoimmune encephalomyelitis (EAE), an animal model of MS.
• To assess the impact of microglia/macrophage depletion on disease symptoms, pathology, and oligodendrocyte preservation during the symptomatic phase of EAE.

Main Methods:

• Utilized the CSF1R inhibitor PLX5622, administered orally, to deplete microglia and macrophages in EAE mice.
• Evaluated animal mobility, weight gain, demyelination, immune activation, and oligodendrocyte survival in treated versus control EAE mice.

Main Results:

• PLX5622 treatment significantly improved animal mobility and weight gain during EAE.
• Microglia/macrophage ablation reduced demyelination and overall immune activation in the CNS.
• Preservation of mature, myelinating oligodendrocytes was observed in white matter lesions of treated animals.

Conclusions:

• Ablating microglia and macrophages during the symptomatic phase of EAE effectively reduces CNS inflammation and pathology.
• This therapeutic strategy may promote remyelination and enhance recovery in MS.
• Targeting microglia and macrophages represents a promising therapeutic avenue for multiple sclerosis treatment.